Auricular Vagus Nerve Stimulation in Constipation-Predominant IBS

Auricular vagus nerve stimulation (taVNS) has emerged as a promising non-invasive neuromodulation therapy for managing constipation-predominant irritable bowel syndrome (IBS-C). A randomized controlled trial has demonstrated that taVNS offers significant benefits across multiple dimensions of IBS-C, targeting both physiological and psychological aspects of the condition. Here’s a detailed breakdown of its effects:

### **Key Findings from the Study**

1. **Symptom Improvement:**

• **Abdominal Pain:** Patients receiving taVNS experienced a notable reduction in abdominal pain compared to those in the sham (placebo) group.
• **Stool Frequency and Bowel Satisfaction:** taVNS significantly improved stool frequency, promoting better bowel movements, and enhanced overall bowel satisfaction.
• **Psychological Symptoms:** Psychological symptoms, such as anxiety and stress, which are commonly associated with IBS-C, were also alleviated.
• **Quality of Life:** The therapy led to a marked improvement in the overall quality of life for patients.

2. **Physiological Mechanisms:**

• **Enhanced Vagal Tone:** taVNS increased vagal tone, which is critical for promoting parasympathetic nervous system activity and regulating gut function.
• **Rectal Sensory Thresholds:** Improved rectal sensory thresholds suggest a normalization of gut hypersensitivity, a hallmark of IBS.
• **Acetylcholine Levels:** taVNS increased acetylcholine levels, which is essential for modulating gut motility and secretion.
• **Gut Microbiome Modulation:** taVNS influenced the gut microbiota composition, with an increase in beneficial bacteria like *Bifidobacterium*. This was accompanied by higher levels of short-chain fatty acids (SCFAs), which play a role in gut health and motility.

3. **Safety and Tolerability:**

• Adverse events associated with taVNS were mild and self-limiting, making it a safe therapeutic option for IBS-C patients.

### **Mechanism of Action:**

The therapeutic benefits of taVNS are attributed to its ability to modulate the **gut–brain–microbiota axis**, a bidirectional communication network between the central nervous system, the enteric nervous system, and the gut microbiota. By stimulating the auricular branch of the vagus nerve, taVNS enhances parasympathetic activity, reduces gut inflammation, and restores gut motility and sensitivity.

### **Advantages of taVNS:**

• **Non-Invasive:** Unlike other invasive neuromodulation techniques, taVNS is applied transcutaneously, making it a more accessible option.
• **Multifaceted Benefits:** It addresses both the physical symptoms (e.g., constipation, pain) and psychological comorbidities (e.g., anxiety) of IBS-C.
• **Gut Microbiome Impact:** The modulation of the gut microbiome and the increase in SCFAs suggest long-term benefits for gut health.

### **Clinical Implications:**

taVNS represents a novel, safe, and effective treatment for IBS-C, particularly for patients who may not respond to conventional therapies such as dietary adjustments, laxatives, or pharmacological agents. Its ability to simultaneously target the gut, brain, and microbiota makes it a comprehensive therapeutic approach.

### **Future Directions:**

Further studies are warranted to:

• Explore the long-term effects of taVNS.
• Identify optimal stimulation parameters (e.g., frequency, duration) for different patient populations.
• Investigate its potential synergy with other IBS-C treatments, such as probiotics or dietary interventions.

In conclusion, auricular vagus nerve stimulation is a groundbreaking therapy for IBS-C, offering significant symptom relief and mechanistic benefits through its modulation of the gut–brain–microbiota axis. Its safety, non-invasiveness, and broad therapeutic effects make it a valuable addition to the IBS-C treatment toolkit.